Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse

European Journal of Pharmacology

Volumn 357, Issue 2-3, 1998, Pages 221-225

  Beales, Philip E ^a   Liddi, Roberto ^a   Giorgini, Angela E ^a   Signore, Alberto ^b   Procaccini, Enrica ^b   Batchelor, Kenneth ^c   Pozzilli, Paolo ^a,b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b POLICLINICO UMBERTO I   (Italy)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Diabetes, type 1; NOD (non obese diabetic) mouse; Troglitazone

Indexed keywords

INSULIN; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HISTOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

AGE FACTORS; ANIMALS; CHROMANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, TYPE 1; FEMALE; INSULIN; MICE; MICE, INBRED NOD; PANCREAS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032544790     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00574-3     Document Type: Article

References (27)

1. Anderson J.T., Cornelius J.G., Jarpe A.J., Winter W.E., Peck A.B. Insulin-dependent diabetes in the NOD mouse model: II. Beta-cell destruction in autoimmune diabetes is a Th1 and not a Th2 mediated event. Autoimmunity. 15:1993;113-122.
2. Bowman M.A., Leiter E.H., Atkinson M.A. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol. Today. 15:1994;115-120.
3. Giorgini A., Scott D., Liddi R., Beales P., Pozzilli P. Troglitazone alters the cytokine production of activated lymphocytes from human donors. Diabetologia. 40(Suppl. 1):1997;A94.
4. Greene M.E., Blumberg B., McBride O.W., Yi H.F., Kronquist K., Kwan K., Hsieh L., Greene G., Nimer S.D. Isolation of the human peroxisome proliferator activated receptor-gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 4:1995;281-299.
5. HMSO (Her Majesty's Stationary Office), London, 1986. Animals (Scientific Procedures) Act.
6. Hofmann C., Lorenz K., Braithwaite S.S., Colca J.R., Palazuk B.J., Hotamisligil G.S., Spiegilman B.M. Altered gene expression for tumour necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology. 134:1994;264-270.
7. Hotamisligil G.S., Speigelman B.M. Tumour necrosis factor-alpha: a key component of the obesity-diabetes link. Diabetes. 43:1994;1271-1278.
8. Ibrahgimi A., Teboul L., Gaillard D., Amre E.Z., Ailhaud G., Young P., Cawthorne M.A., Grimaldi P.A. Evidence for a common mechanism of action for fatty acids and thiazolidinedone antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. 46:1994;1070-1076.
9. 2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 83:1995;813-819.
10. Larson R.S., Springer T.A. Structure and function of leukocyte integrins. Immunol. Rev. 114:1990;181-205.
11. Lasky L.A. Selectins: interpreters of cell specific carbohydrate information during inflammation. Science. 258:1992;964-969.
12. Leslie R.D.G., Pozzilli P. Type 1 diabetes masquerading as Type 2 diabetes: implications for prevention and treatment. Diabetes Care. 17:1994;1214-1219.
13. Lorant D.E., Topham M.K., Whatley R.E., McEver R.P., McIntyrew T.M., Prescott S.M., Zimmerman G.A. Inflammatory roles of P-selectin. J. Clin. Invest. 92:1993;559-570.
14. Makino S., Kunimoto K., Mureoka Y., Mizushima Y., Katagiri K., Tochino Y. Breeding of a non-obese diabetic strain of mice. Exp. Anim. 29:1980;1-13.
15. Mansfield K.J., Beales P.E., Williams A.J.K., Pozzilli P. The breeding, housing and life-maintenance of the non-obese diabetic mouse. Anim. Technol. 43:1992;29-37.
16. N.I.H. Principles of laboratory animal care. Publication no. 83-25, revised, 1985.
17. Ohsumi J., Sakakibara S., Yamaguchi J., Miyadai K., Yoshioka S., Fuliwara T., Horikoshi H., Serizawa N. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology. 135:1994;2279-2282.
18. Pozzilli P., Signore A., Williams A.J.K., Beales P.E. NOD mouse colonies around the world - recent facts and figures. Immunol. Today. 14:1993;193-196.
19. Pozzilli P., Carotenuto P., Delitala G. Lymphocyte traffic and homing into target tissue and the generation of endocrine autoimmunity. Clin. Endocrinol. 41:1994;545-554.
20. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes. 44:1995;859-862.
21. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
22. Shimabukuro M., Koyama K., Lee Y., Unger R.H. Leptin- or Troglitazone-induced lymphopenia protects islets from interleukin 1a cytotoxicity. J. Clin. Invest. 100:1997;1750-1754.
23. Signore A., Pozzilli P., Gale E.A.M., Andreani D., Beverley P.C.L. The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice. Diabetologia. 32:1989;282-289.
24. Signore A., Procaccini E., Toscano A.M., Ferretti E., Williams A.J.K., Beales P.E., Cugini P., Pozzilli P. Histological study of pancreatic beta cell loss in relation to the insulitis process in the non-obese diabetic mouse. Histochemistry. 101:1994;263-269.
25. Sironi A.M., Vichi S., Gastaldelli A., Anichini R., Garbin U., Cominacini L., Seghieri G., Ferrannini E. Effects of troglitazone on insulin sensitivity and cardiovascular risk factors (CVRF) in NIDDM. Diabetes. 45((A680)(Suppl. 2)):1986;185A.
26. Tochino, Y., 1986. Discovery and breeding of the NOD mouse. In: Tauri, S., Tochino, Y., Nokada, K. (Eds.), Insulitis and Type 1 Diabetes - Lessons from the NOD Mouse. Academic Press, Tokyo, pp. 3-10.
27. Yu K., Bayona W., Kallen C.B., Harding H.P., Ravera C.P., McMahon G., Brown M., Lazar M.A. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270:1995;23975-23983.